Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Coherus Biosciences, retaining the price target of $4.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of Coherus Biosciences’ innovative oncology pipeline. The recent Nobel Prize in Physiology or Medicine, awarded for discoveries in peripheral immune tolerance and the role of regulatory T cells (Tregs), underscores the relevance of Coherus’ CHS-114, an anti-CCR8 antibody designed to deplete intratumoral Tregs and enhance immune response against tumors. This scientific recognition has brought attention to the therapeutic potential of targeting CCR8, a mechanism that is gaining interest from major pharmaceutical companies.
Furthermore, Coherus is actively advancing CHS-114 in multiple clinical programs, with significant data readouts expected in 2026, which could serve as catalysts for the company’s stock. The company’s transition from biosimilars to a focus on oncology, coupled with the rising investor interest and recent stock performance, supports McCarthy’s optimistic outlook. The upcoming Society for Immunotherapy of Cancer (SITC) events, where Coherus will showcase CHS-114, are expected to further enhance the visibility and credibility of their oncology efforts, reinforcing the Buy recommendation.